Our services span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
Site and patient identification, enrolment and engagement
Integrated services that cover planning, management, execution and analysis.
We have extensive experience in a broad range of therapeutic
areas. Managing studies in all major geographies, we have
established solid working relationships with the world’s
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
ICON has recently led the development of 14 vaccines resulting in FDA/EMA approvals
We develop integrated technologies to significantly enhance
the efficiency and productivity of clients’ drug and device
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Digital solutions that increase efficiency in clinical trials by driving site performance.
BioPharma companies and Medical Devices manufacturers face
growing operational, regulatory and economic challenges. ICON
provides analysis and key insights on these challenges, with
practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
Reduce post market study costs with Real World Data
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
Innovative solutions to help pharma, biotech and medical device companies to market faster. Arrange a meeting.
Exploring the innovative use of data to enable powerful collaboration.
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
Acquisition enhances ICON’s patient access in Europe and Africa
Making it easier for the site and patient
Develop the right business strategy to successfully navigate MDR/IVDR
Increasing efficiency through automation
Primary research evaluating ICER’s influence over payers and manufactures
Digital health solutions for clinical R&D efficiency and patient outcomes
Insights you need for successful biosimilar commercialisation
Determine the right design, assessments and endpoints in your pain study
Despite multiple challenges, RWE clearly has huge potential to
inform healthcare stakeholders.
Explore how conducting a thorough data-driven feasibility
assessment sets sponsors up for success in the operational
aspects of their trials.
ICON expert Dr. Uma Arumugam takes a look at the advancements in digital
applications and technology impacting clinical drug development.
ICON experts Bart Chapman and Shanthi Sundaramoorthy answer common questions about ophthalmology studies, and those relating to biosimilars.
Early access schemes demand new ways of performing health
Manufacturers need to employ new methods and tools to maximise
the effectiveness of their efforts in bringing new devices to
Learn 5 common barriers to Real World Data (RWD) harmonisation
and insights on how to overcome these challenges.
ICON's Travis Tingey attended the recent ePharma IMPACT conference and shares his thoughts on notable trends and themes.
ICON Medical Communications attended the 2019 MAPS Annual Meeting and share key themes and trends.